Its interactions with the vagus nerve have been investigated in the context of brain-gut axis effects, including gastroparesis (delayed gastric emptying), where BPC-157 has shown consistent pro-motility effects in preclinical models through vagal cholinergic pathways
Theyre likely to be taking these drugs for shorter durations, so any consumer-facing company thats adjusting product and marketing strategies in response to the rise in usage rates were seeing for these drugs should also be taking into account that a larger underlying user base means that we'll be seeing a growing number of consumers who are also stopping and ceasing these drugs over time as well. How To Respond In addressing how retailers and food and beverage companies should respond, Circana said that while some consumers will resume their pre-GLP-1 purchase habits when they cease treatment, for many others, varying forms of the medication, supplements and CPG food and beverage will play critical roles in how individuals manage their conditions. Some areas of opportunity include: Product innovation: Develop and promote products that align with the dietary needs of GLP-1 users, Circana said
Whats the Buzz The Bee Healthy Blog Does United Healthcare Cover Wegovy for Weight Loss
Table 2 Peptide concentrations (M) evaluated in the IVIP assay
to help establish a structured eating environment
Mochi Health is one of the 14 companies recently sued by Novo, and is also dealing with a lawsuit from Eli Lilly
